BR0314700A - Derivados que compreendem esteróis e/ou estanóis e classes especìficas de agentes antiinflamatórios e seu uso no tratamento ou prevenção de doença cardiovascular - Google Patents

Derivados que compreendem esteróis e/ou estanóis e classes especìficas de agentes antiinflamatórios e seu uso no tratamento ou prevenção de doença cardiovascular

Info

Publication number
BR0314700A
BR0314700A BR0314700-2A BR0314700A BR0314700A BR 0314700 A BR0314700 A BR 0314700A BR 0314700 A BR0314700 A BR 0314700A BR 0314700 A BR0314700 A BR 0314700A
Authority
BR
Brazil
Prior art keywords
derivatives
inflammation
cardiovascular disease
stanols
sterols
Prior art date
Application number
BR0314700-2A
Other languages
English (en)
Inventor
James P Kutney
Haydn P Pritchard
Yangbing Ding
Kishor M Wasan
Original Assignee
Forbes Medi Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/255,558 external-priority patent/US20040236125A1/en
Application filed by Forbes Medi Tech Inc filed Critical Forbes Medi Tech Inc
Publication of BR0314700A publication Critical patent/BR0314700A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"DERIVADOS QUE COMPREENDEM ESTERóIS E/OU ESTANóIS E CLASSES ESPECìFICAS DE AGENTES ANTIINFLAMATóRIOS E SEU USO NO TRATAMENTO OU PREVENçãO DE DOENçA CARDIOVASCULAR". A presente invenção fornece, em um aspecto, derivados inusitados que compreendem esteróis e/ou estanóis e um fármaco antiinflamatório não-esteróide (NSAID) selecionado entre ácidos salicílicos e ácidos aril-alcanóicos, incluindo sais destes derivados, e tendo uma ou mais das seguintes fórmulas: a) R~ 2~-(CH~ 2~)~ n~-CO-R, b) R~ 2~R, c) R~ 2~-CO-CO-OR, d) fórmula (I), onde R é um grupamento esterol ou estanol, R~ 2~ é derivado de um ácido salicílico ou um ácido aril-alcanóico, e n = 1 a 5. Fornece-se também composições farmacêuticas que compreendem um ou mais desse derivados inusitados, e métodos para tratar ou prevenir doença cardiovascular e suas condições subjacentes, incluindo, sem limitações, aterosclerose, hipercolesterolemia, hiperlipidemia, hipertensão, trombose, doença das artérias coronárias, e para tratar e reduzir inflamação, inclusive inflamação de placas coronárias, inflamação induzida por bactérias, inflamação induzida por vírus e inflamação associada a dor aguda e procedimentos cirúrgicos, compreendendo administrar a um animal, particularmente um ser humano, uma quantidade atóxica e terapeuticamente eficaz de um ou mais desses compostos ou um seu sal biologicamente aceitável.
BR0314700-2A 2002-09-25 2003-09-25 Derivados que compreendem esteróis e/ou estanóis e classes especìficas de agentes antiinflamatórios e seu uso no tratamento ou prevenção de doença cardiovascular BR0314700A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/255,558 US20040236125A1 (en) 2002-09-25 2002-09-25 Novel structures and compositions comprising sterols and/or stanols and specific classes of anti-inflammatory agents and use thereof in treating or preventing cardiovascular disease, its underlying conditions including hyperlipidemia and other disorders having inflammation as part of their aetiology or presentation
US66484303A 2003-09-16 2003-09-16
PCT/CA2003/001412 WO2004029068A1 (en) 2002-09-25 2003-09-25 Derivatives comprising sterols and/or stanols and specific classes of anti-inflammatory agents and use thereof in treating or preventing cardiovascular disease

Publications (1)

Publication Number Publication Date
BR0314700A true BR0314700A (pt) 2005-07-26

Family

ID=32044971

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314700-2A BR0314700A (pt) 2002-09-25 2003-09-25 Derivados que compreendem esteróis e/ou estanóis e classes especìficas de agentes antiinflamatórios e seu uso no tratamento ou prevenção de doença cardiovascular

Country Status (10)

Country Link
EP (1) EP1556406A1 (pt)
JP (1) JP2006503840A (pt)
KR (1) KR20050084572A (pt)
CN (1) CN1684971A (pt)
AU (1) AU2003266885A1 (pt)
BR (1) BR0314700A (pt)
CA (1) CA2499817A1 (pt)
NO (1) NO20051932L (pt)
RU (1) RU2005112247A (pt)
WO (1) WO2004029068A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0329667D0 (en) 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0513881D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
DE102004008035A1 (de) * 2004-02-19 2005-09-08 Symrise Gmbh & Co. Kg Verwendung von (2-Hydroxyphenyl)-alkoholen sowie diese Verbindungen enthaltende kosmetische oder therapeutische Formulierungen
GB0513883D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
ES2580331T3 (es) * 2012-05-10 2016-08-23 Beta Innov Derivados de esterol, método para preparar los mismos, composiciones farmacéuticas que contienen los mismos y uso de los mismos para el tratamiento de glioblastomas múltiples
CN104434927A (zh) * 2014-12-16 2015-03-25 吉林农业大学 丙二酸双环戊烷并多氢菲酯b在制备降血压药物中的应用
CN104530167B (zh) * 2014-12-16 2016-02-24 吉林农业大学 水杨酸环戊烷并多氢菲酯a及其提取方法和药物用途
CN111053741B (zh) * 2019-12-31 2021-09-28 江苏省中医院 一种用于治疗炎症性肠病的基于β-谷甾醇与5-ASA的口服多敏感胶束前药
CN114014905B (zh) * 2021-12-03 2023-07-21 浙江科技学院 靶向PPARγ的甘草次酸类衍生物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19518221A1 (de) * 1995-05-10 1996-11-14 Schering Ag Verwendung nichtsteroidaler Entzündungshemmer zur Verbesserung der physiologischen Verträglichkeit partikulärer pharmazeutischer Zubereitungen
AU4891699A (en) * 1998-07-20 2000-02-14 Forbes Medi-Tech Inc. Compositions comprising phytosterol, phytostanol or mixtures of both and omega-3fatty acids or derivatives thereof and use of the composition in treating or preventing cardiovascular disease and other disorders
ATE286064T1 (de) * 1999-06-21 2005-01-15 Forbes Medi Tech Inc Aromatische und heterozyklische derivate von phytosterolen und/oder phytostanolen zur behandlung von gefässkrankheiten
CA2377492A1 (en) * 1999-06-23 2001-01-04 Honming Chen Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
AU2001242130A1 (en) * 2000-03-07 2001-09-17 Forbes Medi-Tech Inc. Novel derivatives comprising phytosterols and/or phytostanols and alpha-lipoic and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders
MXPA03003701A (es) * 2000-10-25 2005-07-01 Forbes Medi Tech Inc Estructuras novedosas que comprenden fitosterol y/o fitostanol y acido ascorbico y uso de las mismas como agentes de regulacion de peso.
PL371436A1 (en) * 2002-01-30 2005-06-13 Pharmacia Corporation Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders

Also Published As

Publication number Publication date
WO2004029068A1 (en) 2004-04-08
RU2005112247A (ru) 2006-01-20
JP2006503840A (ja) 2006-02-02
CN1684971A (zh) 2005-10-19
CA2499817A1 (en) 2004-04-08
EP1556406A1 (en) 2005-07-27
NO20051932L (no) 2005-04-20
AU2003266885A1 (en) 2004-04-19
KR20050084572A (ko) 2005-08-26

Similar Documents

Publication Publication Date Title
NO20051932L (no) Derivater omfattende steroler og/eller stanoler og spesifikke klasser av antiinflammatoriske midler og anvendelse derav ved behandling eller forebyggelse av kardiovaskulaer sykdom.
CA2237306C (en) Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs
CA2105529C (en) Composition comprising non-steroidal anti-inflammatory agent and effectively non-antibacterial tetracycline
ES2342609T3 (es) Agente terapeutico para hiperlipemia que comprende pitavastatinas y acido eicosapentaenoico.
Galanakis et al. Synthesis and pharmacological evaluation of amide conjugates of NSAIDs with L-cysteine ethyl ester, combining potent antiinflammatory and antioxidant properties with significantly reduced gastrointestinal toxicity
DE69912313D1 (de) Colchinolderivate als gefässschädigende mittel
BR0215240A (pt) Derivados de calcona e seu uso no tratamento de doenças
CA2293605A1 (en) Pharmaceutical preparations containing hydrosoluble ketoprofen salts and their application
BRPI0513565A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir uma atividade de proteìna cinase, e para tratar um paciente tendo uma condição que é mediada por atividade de proteìna cinase, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
NO20071058L (no) Risedronatsammensetninger og deres fremgangsmater for anvendelse
RU95102778A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования потерь костной ткани и снижения уровня холестерина в сыворотке, фармацевтический препарат, содержащий 2-фенил-3-ароилбензотиофен
BR9815442A (pt) Liberação terapêutica dirigida de compostos de vitamina d
US20080227747A1 (en) Composition and methods for treating or preventing degenerative joint and cardiovascular conditions
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
WO2008157771A1 (en) Composition and method for treating connective tissue damage by transmucosal administration
DE59608698D1 (de) Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure
ES2344677T3 (es) Medicamentos para enfermedades articulares.
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
DE68911891D1 (de) Verwendung von Acetyl-L-carnitin zur Behandlung von Katarakt, sowie pharmazeutische Zusammensetzungen für eine derartige Behandlung.
ATE541567T1 (de) Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten
JP2001521539A (ja) 炎症及び疼痛メディエーターのＮｆ−κＢ依存性生成阻害剤としてのイブプロフェンチオエステル（炎症及び疼痛メディエーターのＮｆ−κＢ依存性生成阻害剤としてのアリールプロピオン酸、アリール酢酸及びサリチル酸塩のＣｏＡチオエステル）
ES2257282T3 (es) Melagatran para el tratamiento de inflamacion.
HK1087039A1 (en) Use of biphosphonate in preparing medical kit and a kit used for increasing bone mass
RU2408380C1 (ru) Лекарственная композиция для лечения болезней суставов (варианты)
BRPI0620983A2 (pt) uso de derivados de triazina para a fabricação de um medicamento e composição farmacêutica compreendendo os referidos derivados

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE 4A., 5A., 6A. E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010.